Antihypertensive drugs and risk of COVID-19?,The Lancet Respiratory Medicine

当前位置： X-MOL 学术 › Lancet Respir. Med. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Antihypertensive drugs and risk of COVID-19?
The Lancet Respiratory Medicine ( IF 38.7 ) Pub Date : 2020-03-26 , DOI: 10.1016/s2213-2600(20)30156-9
Kevin Bryan Lo ₁ , Peter A McCullough ₂ , Janani Rangaswami ₁

Affiliation

Lei Fang and colleagues postulate that because severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) binds to the angiotensin-converting enzyme 2 (ACE2) receptor to facilitate host cell entry,^, disease severity and mortality of coronavirus disease 2019 (COVID-19) might be increased in patients taking angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) during the COVID-19 pandemic, because the ACE2 receptor might be upregulated with use of ACEIs and ARBs.

中文翻译：

降压药和COVID-19的风险？

雷罚嗯及其同事推测，因为严重急性呼吸综合征冠状病毒2（SARS-CoV的-2）结合于血管紧张素转化酶2（ACE2）受体，以促进进入宿主细胞，^，疾病的严重程度和疾病冠状2019的死亡率（COVID- 19）在COVID-19大流行期间服用血管紧张素转换酶抑制剂（ACEIs）和血管紧张素受体阻滞剂（ARBs）的患者可能会增加，因为使用ACEI和ARB可能会上调ACE2受体。

更新日期：2020-03-27

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文